Roche and Hansoh Ink Cancer Drug Collaboration
The pharmaceutical companies have launched a multi-billion dollar partnership to develop experimental cancer treatments.
Updated on Oct. 19, 2026 in Cancer
Live Poll
Do you trust that major pharmaceutical drug collaborations prioritize patient needs over corporate profits?
Roche and Hansoh Pharmaceutical have entered a new collaboration to develop experimental antibody-drug conjugates for cancer treatment. Hansoh will receive $400 million in an initial upfront payment as part of the agreement.
Why it matters
The collaboration marks a significant expansion in oncology research, with the potential for milestone payments to exceed $15 billion across the portfolio. It builds upon a prior partnership between the two companies established in 2025.
Hansoh is set to receive $400 million upfront and an additional $110 million on the first anniversary of the deal, with total milestone potential exceeding $15 billion. The deal follows an October 2025 agreement worth $1.45 billion in milestones.
The players
Roche
Roche is a Swiss multinational healthcare company that operates worldwide in the pharmaceutical and diagnostics sectors.
Hansoh Pharmaceutical
Hansoh Pharmaceutical is a China-based company focused on the discovery and development of innovative medicines for oncology and other therapeutic areas.
The details
The agreement includes two Hansoh programs in preclinical development, with Hansoh leading research through Phase Ia trials before Roche takes over global development. Hansoh maintains rights to the drug portfolio in mainland China, Hong Kong, Macau, and Taiwan, while positioning itself for additional proceeds from U.S. commercialization.
Timeline
October 2025: Companies signed an initial agreement for HS-20110.
October 19, 2026: Companies announced the new portfolio collaboration.
The Big Picture
This deal expands upon the 2025 agreement for HS-20110, signaling a deeper integration of Roche and Hansoh's research capabilities. The collaboration follows a pattern of global pharmaceutical leaders partnering with regional innovators to accelerate the development of antibody-drug conjugates.
This development could eventually lead to new treatment options for cancer patients, though availability remains dependent on future clinical trial success. There is no immediate impact on current patient routines or treatment costs.
The takeaway
This partnership highlights the continued industry focus on antibody-drug conjugates as a key pillar for future oncology therapeutics. Investors and patients should monitor progress in the preclinical phase as the companies move toward clinical trials.
Further reading
For more on evolving treatments, visit the Cancer section.
Live Poll
Do you trust that major pharmaceutical drug collaborations prioritize patient needs over corporate profits?
